A team of researchers has found new insight into why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings may help improve future ways to deliver ...

A multi-institutional clinical trial conducted at the UNC Lineberger Comprehensive Cancer Center and 21 other U.S. sites found that a single administration of autologous tumor-infiltrating lymphocyte ...

Amtagvi approval with FY25 sales significantly lower than initial guidance and significant share dilution. Learn more about ...

Obsidian Therapeutics, Inc., a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today ...

Scientists from the Moffitt Cancer Center say they now have a better understanding why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings ...

Oral presentation of Phase 1 results from Agni-01 multicenter study of cryopreserved OBX-115, a novel IL2-sparing engineered TIL cell therapy armored with pharmacologically regulatable membrane-bound ...

Until recently, solid tumors — which make up 90% of cancer diagnoses — had no cell therapy. However, that changed in 2024, when the FDA approved a treatment from Iovance Biotherapeutics for advanced ...

Patient recounts IL‑2 therapy chills, rigors, ICU seizure scare, and recovery—what treatment feels like and why monitoring matters. This episode takes a closer look at the biology behind TIL therapy.

Next-Generation Platform Expands into Solid Tumors Representing 100,000+ U.S. Deaths Annually SAN CARLOS, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a ...